Research and Clinical Trials
City of Hope has long been a leader in lymphoma research. Our research projects have been funded by the National Cancer Institute and many other research-based organizations. We collaborate with other leading research institutions to develop tomorrow’s breakthroughs today. With our extensive program of clinical trials, City of Hope can provide our patients access to novel therapies, including many that are not available elsewhere.
Our Developmental Therapeutics Program has an active portfolio of trials for patients with recurrent lymphoma, including trials of new chemotherapy and immunotherapy drugs. We are also actively involved in survivorship research.
City of Hope’s
Lymphoma Specialized Program of Research Excellence (SPORE)
program is focused on developing translational studies to improve the detection and therapy of Hodgkin and non-Hodgkin lymphoma. It aims to develop novel approaches derived from molecular and immunologic studies of T cell and antibody-based therapies. Its goal is also to create lymphoma therapies that will reduce toxicities associated with current treatment regimens. Those new therapies can then be translated for use in older patient populations.
To learn more about our clinical trials program and specifically about trials for lymphoma,